<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01511003</url>
  </required_header>
  <id_info>
    <org_study_id>PRGRA-10-04-KOR</org_study_id>
    <nct_id>NCT01511003</nct_id>
  </id_info>
  <brief_title>A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)</brief_title>
  <acronym>TREASURE</acronym>
  <official_title>An Open- Label, Single-arm, Phase 4 Study to Assess the Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against DMARDs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Korea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess efficacy and safety of tacrolimus in active rheumatoid arthritis&#xD;
      patients who showed unsuccessful response to existing DMARDs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 5, 2011</start_date>
  <completion_date type="Actual">May 11, 2015</completion_date>
  <primary_completion_date type="Actual">May 11, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ACR20 response rate 6 months post dose</measure>
    <time_frame>Baseline and 6 months post dose</time_frame>
    <description>ACR20 is 20% improvement in ACR (American College of Rheumatology) core set</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR50 response rates at month 6</measure>
    <time_frame>Baseline and at month 6</time_frame>
    <description>ACR50 is 50% improvement in ACR (American College of Rheumatology) core set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR70 response rates at month 6</measure>
    <time_frame>Baseline and at month 6</time_frame>
    <description>ACR70 is 70% improvement in ACR (American College of Rheumatology) core set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAS28 from baseline to 6 months</measure>
    <time_frame>Baseline and at month 6</time_frame>
    <description>DAS (Disease Activity Score in Rheumatoid Arthritis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone loss rate from baseline to 6 months</measure>
    <time_frame>Baseline and at month 6</time_frame>
    <description>comparative factors for bone loss rate: bone mineral densitometry [BMD], bone turnover marker test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse events, vital signs and lab-tests</measure>
    <time_frame>For 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Tacrolimus group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>oral</description>
    <arm_group_label>Tacrolimus group</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who have rheumatoid arthritis for 6 months or longer based on American&#xD;
             College of Rheumatology (ACR) diagnostic criteria&#xD;
&#xD;
          -  Subjects who used more than 1 Disease Modifying Antirheumatic Drug (DMARD) including&#xD;
             MTX (methotrexate) for 6 months or longer&#xD;
&#xD;
          -  Subjects with ESR (erythrocyte sedimentation rate) ≥ 28mm/h or CRP (C-reactive&#xD;
             protein)≥ 1.0 mg/dL&#xD;
&#xD;
          -  Subjects with ≥ 3 swollen joints out of 66 joints assessed&#xD;
&#xD;
          -  Subjects with ≥ 6 tender joints out of 68 joints assessed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing women, or subjects who plan to become pregnant within 6 months or&#xD;
             whose screening test results show pregnancy cannot be ruled out&#xD;
&#xD;
          -  Subjects with previous experience of tacrolimus (excluding external preparations)&#xD;
&#xD;
          -  Subjects with renal dysfunction or with serum creatinin &gt; 1.4 mg/dL at screening&#xD;
&#xD;
          -  Following subjects with hepatic dysfunction: viral infection, non-viral infection,&#xD;
             hepatic cirrhosis, and Serum Glutamic Oxaloacetic Transaminase / Serum Glutamic&#xD;
             Pyruvic Transaminase (SGOT/SGPT) exceeding twice the upper limit of normal at&#xD;
             screening&#xD;
&#xD;
          -  Subjects with pancreatitis, uncontrolled diabetes or complication(s) or with HbA1c &gt;&#xD;
             6.4% at screening&#xD;
&#xD;
          -  Subjects complicated with hyperkalemia or with serum potassium level &gt;5.5 mEq/L at&#xD;
             screening&#xD;
&#xD;
          -  Subjects with history of heart disease (ischemic heart disease, arrhythmia requiring&#xD;
             treatment, and heart failure), etc or complications&#xD;
&#xD;
          -  Subjects complicated with severe respiratory disease and infection&#xD;
&#xD;
          -  Subjects with history of malignant tumor or complication(s) (However, the subjects who&#xD;
             are considered to have no risk of recurrence with malignant tumor untreated for 5&#xD;
             years or longer can enter the study. The subjects who succeeded in treatment for basal&#xD;
             cell or squamous cell carcinoma of skin can also enter the study.)&#xD;
&#xD;
          -  Subjects who were treated with other investigational product(s) within 3 months before&#xD;
             screening&#xD;
&#xD;
          -  Other subjects who are considered ineligible for the study by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=151</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 4, 2012</study_first_submitted>
  <study_first_submitted_qc>January 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2012</study_first_posted>
  <last_update_submitted>August 10, 2018</last_update_submitted>
  <last_update_submitted_qc>August 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>calcineurin inhibitor</keyword>
  <keyword>Prograf</keyword>
  <keyword>Rheumatoid arthritis (RA)</keyword>
  <keyword>Tacrolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

